- “Europe aims to reduce cancer deaths by 15 pct by 2012” (Reuters)
- “US FDA staff: Problems in River Plate drug studies” (Reuters)
- “FDA says Ista eye drug has no serious side effects” (The Associated Press)
- “FDA wants more info on GSK’s nausea drug casopitant” (PharmaTimes)
- “Matrixx recalls Zicam nasal cold products” (The Associated Press)
- “FDA rejects Glaxo’s nausea therapy Rezonic” (FierceBiotech)
- “Goldman Sachs raises Teva price target to $54” (Globes)
- “Emergent gets boost from FDA” (Business Gazette)
- “Nucyntatm Now Available For Pain Relief” (Pharmaceutical Business Review)
- “Expecting FDA Approval for Eurand’s Zenpep” (Seeking Alpha)
- “Acura says pain drug to miss June 30 approval date” (Reuters)
- “DiaGenic to Provide MCI Biomarkers for Merz Pharmaceuticals” (Press release issued by Diagenic ASA and Merz Pharmaceuticals, PRNewsWire)
- “FTC pushes for ban on drug patent settlements” (The News Journal)
- “Grant zeroes in on novel asthma diagnosis, treatment” (Press release issued by UC Davis Asthma Network, Media NewsWire)
THE LATEST WORD
Top Industry Stories – June 24, 2009
Posted on June 24th, 2009 | by Rxmedyn | No Comments »Posted in Industry Stories
SUBSCRIBE-
Recent Posts
Archives
Careers | © 2009 Medical Dynamics